Survival poor after recurrence of early-stage ovarian cancer

April 2008
Hem/Onc Today;4/25/2008, Vol. 9 Issue 7, p32
The article focuses on research on the survival after recurrence of early-stage ovarian cancer. According to a study presented by Deanna Teoh, MD, obstetrics and gynecology resident at the University of California, San Francisco, on 74 patients with high-risk early-stage epithelial ovarian cancer and randomly assigned to three or six cycles of carboplatin and paclitaxel. Findings showed that survival from said condition is poor and comparable to advanced-stage.


Related Articles

  • Ovarian cancer in elderly patients: carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in late relapse: a Gynecologic Cancer Intergroup (GCIG) CALYPSO sub-study. Kurtz, J. E.; Kaminsky, M. C.; Floquet, A.; Veillard, A. S.; Kimmig, R.; Dorum, A.; Elit, L.; Buck, M.; Petru, E.; Reed, N.; Scambia, G.; Varsellona, N.; Brown, C.; Pujade-Lauraine, E. // Annals of Oncology;Nov2011, Vol. 22 Issue 11, p2417 

    Background: CALYPSO (CAeLYx in Platinum Sensitive Ovarian) patients compared carboplatin–pegylated liposomal doxorubicin (C–PLD) with carboplatin–paclitaxel (C–P) in patients with late-relapsing recurrent ovarian cancer (ROC). We analyzed outcomes in patients...

  • Cancers gynécologiques. Petit, T. // Oncologie;Aug2011, Vol. 13 Issue 8, p477 

    No abstract available.

  • Primary squamous cell carcinoma associated with ovarian endometriosis: a case report and literature review. Yamakawa, Yoshihiro; Ushijima, Michiyo; Kato, Kiyoshi // International Journal of Clinical Oncology;Dec2011, Vol. 16 Issue 6, p709 

    Primary squamous cell carcinoma (SCC) associated with ovarian endometriosis is extremely rare and has a poor prognosis due to insufficient information on the optimal postoperative treatment. Here, we describe the response of this tumor to the administration of paclitaxel-carboplatin. A...

  • Decreased ARID1A expression is correlated with chemoresistance in epithelial ovarian cancer. Yokoyama, Yoshihito; Matsushita, Yoko; Shigeto, Tatsuhiko; Futagami, Masayuki; Mizunuma, Hideki // Journal of Gynecologic Oncology;2014, Vol. 25 Issue 1, p58 

    Objective: Loss of ARID1A is related to oncogenic transformation of ovarian clear cell adenocarcinoma. The present study was conducted in epithelial ovarian cancer of all tissue types to investigate whether an increased or decreased expression level of ARID1A can be a prognostic factor for...

  • Update on randomized trials on recurrent disease. González-Martín, A. // Annals of Oncology;Dec2013 Supplement 10, Vol. 24, px48 

    Approximately 75% of patients with advanced ovarian cancer will have a recurrence of their disease within the first 3 years after upfront surgery and paclitaxel–carboplatin-based chemotherapy. An optimal choice of treatment of patients with a recurrence is an important issue, and several...

  • Novel Facts About FAK: New Connections to Drug Resistance? Annunziata, Christina M.; Kohn, Elise C. // JNCI: Journal of the National Cancer Institute;10/2/2013, Vol. 105 Issue 19, p1430 

    The article discusses research being done on taxane resistance chemotherapy. It references the study "Role of Focal Adhesion Kinase in Regulating YB-1-mediated Paclitaxel Resistance in Ovarian Cancer," by Y. Kang et al. published in the 2013 issue of the Journal of National Institute." The study...

  • Copy number changes of 4-gene set may predict early relapse in advanced epithelial ovarian cancer after initial platinum-paclitaxel chemotherapy. Ning Li; Jin-Lin Hou; Zhi-Zhou Shi; Xiao-Guang Li; Nan Li; Yang-Chun Sun; Xin Xu; Yan Cai; Xun Zhang; Kai-Tai Zhang; Ming-Rong Wang; Ling-Ying Wu // American Journal of Cancer Research;2014, Vol. 4 Issue 3, p285 

    For advanced epithelial ovarian cancer (EOC), time to recurrence (TTR) is an important indicator to gauge the therapeutic efficacy of postoperative adjuvant chemotherapy. Our objective was to determine the genes that could potentially distinguish patients with short versus long TTR after initial...

  • Paclitaxel.  // Reactions Weekly;Sep2015, Vol. 1569 Issue 1, p163 

    The article is about a patient who was undergoing chemotherapy along with paclitaxel for metastatic ovarian cancer, after five cycles of the treatment vision loss was reported which as attributed to the usage of paclitaxel, and subsequently it was withdrawn.

  • Activity of chemotherapy in mucinous ovarian cancer with a recurrence free interval of more than 6 months: results from the SOCRATES retrospective study. Pignata, Sandro; Ferrandina, Gabriella; Scarfone, Giovanna; Scollo, Paolo; Odicino, Franco; Cormio, Gennaro; Katsaros, Dionyssios; Villa, Antonella; Mereu, Liliana; Ghezzi, Fabio; Manzione, Luigi; Lauria, Rossella; Breda, Enrico; Alletti, Desiderio Gueli; Ballardini, Michela; Lombardi, Alessandra Vernaglia; Sorio, Roberto; Mangili, Giorgia; Priolo, Domenico; Magni, Giovanna // BMC Cancer;2008, Vol. 8, Special section p1 

    Background: Mucinous ovarian carcinoma have a poorer prognosis compared with other histological subtypes. The aim of this study was to evaluate, retrospectively, the activity of chemotherapy in patients with platinum sensitive recurrent mucinous ovarian cancer. Methods: The SOCRATES study...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics